- Home
- PCRX
as 07-26-2024 4:00pm EST
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.
Upcoming Earnings Alert:
Get ready for potential market movements as Pacira BioSciences Inc. PCRX prepares to release earnings report on 30 Jul 2024.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | TAMPA |
| Market Cap: | 1.3B | IPO Year: | 2011 |
| Target Price: | $43.60 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.45 | EPS Growth: | N/A |
| 52 Week Low/High: | $19.34 - $40.16 | Next Earning Date: | 07-30-2024 |
| Revenue: | $681,754,000 | Revenue Growth: | 1.88% |
| Revenue Growth (this year): | 4.77% | Revenue Growth (next year): | 9.60% |
Stock Insider Trading Activity of Pacira BioSciences Inc. (PCRX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| HASTINGS PAUL J | PCRX | Director | Jun 12 '24 | Sell | $28.38 | 880 | $24,974.40 | 12,724 | SEC Form 4 |
| WILLIAMS KRISTEN | PCRX | Chief Administrative Officer | Jun 12 '24 | Sell | $28.38 | 7,452 | $211,487.76 | 102,912 | SEC Form 4 |
| PACE GARY W | PCRX | Director | Mar 6 '24 | Sell | $29.67 | 1,066 | $31,628.22 | 140,384 | SEC Form 4 |
| PACE GARY W | PCRX | Director | Mar 6 '24 | Sell | $30.81 | 28,257 | $870,598.17 | 112,127 | SEC Form 4 |
| PACE GARY W | PCRX | Director | Mar 6 '24 | Sell | $30.60 | 90,000 | $2,754,000.00 | 22,127 | SEC Form 4 |
Latest Pacira BioSciences Inc. News
PCRX Breaking Stock News: Dive into PCRX Ticker-Specific Updates for Smart Investing
Argus Research
3 days ago
PCRX: Lowering target price to $21.00
GlobeNewswire
3 days ago
Pacira to Report Second Quarter 2024 Financial Results on Tuesday July 30, 2024
Medical Device Network
4 days ago
Nanotechnology in medicine: Who are the leading public companies?
Zacks
9 days ago
Should Value Investors Buy Pacira BioSciences (PCRX) Stock?
Argus Research
10 days ago
PCRX: What does Argus have to say about PCRX?
GlobeNewswire
16 days ago
Centers for Medicare and Medicaid Propose New Reimbursement for EXPAREL in All Outpatient Surgical Environments Beginning January 1, 2025
Argus Research
17 days ago
PCRX: Lowering target price to $22.00
Argus Research
24 days ago
PCRX: Lowering target price to $24.00
Compare PCRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PCRX Pacira BioSciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.